NJPharma, a sister company of Portland, Conn.-based CTPharma, is proposing a new study at Rutgers University on the impact of marijuana treatment as a way to aid patients in and outside of New Jersey.
The proposal was announced as the state prepares to expand licensing for its Medical Marijuana Program.
In its New Jersey license application, NJPharma said it has already engaged Rutgers in preliminary discussions for a new study.
“New Jersey is establishing itself as a leader in the field and we need to provide the best American-based pharma marijuana product and to produce the research that will offer the most effective treatments,” said NJPharma Chief Executive Officer Tom Schultz.
NJPharma’s goal is to focus on research and health,” said Schultz. “The current 61,000 New Jerseyans in the state medical marijuana program can potentially grow to 180,000. The 1,000 doctors and 2,380 caregivers will surely increase as well. They deserve the best product and best science as we look to participate in New Jersey’s program.”
Over the past 100 years, Americans have come to expect their pharmaceutical products to meet the FDA’s safety and efficacy standards. Recently, CTPharma announced a first of its kind study with Yale University School of Medicine.
“The Food and Drug Administration’s stated concern with CBD products highlights the consumer confusion that can ensue from such alerts,” said Rino Ferrarese, CTPharma chief operating officer. “We have the knowledge and track record to use plant-derived cannabinoid formulations and to prove their safety and efficacy to any standards, including the FDA’s, right here in America. Being the best American producer of medical cannabis plant product is not enough.
“In short, the promise of medical marijuana is too encouraging to be left to chance and we are at the forefront of providing knowledge to the consumer through University-based research,” Ferrarese said.
In response to NJPharma’s proposal Rutgers said that the university looks forward to future discussions to advance the important field of research in a compliant, ethical, and secure manner.